By Basem M. William, MD On Monday, the Director of the Division of Hematology Products in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA), Ann Farrell, MD, chaired the two special ASH-FDA Joint Symposia focusing on new...
By Basem M. William, MD One of the major leaps in hematopoietic stem cell transplantation (HSCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to approximately 75 percent of patients who do...
By Basem M. William, MD, MRCP(UK), FACP Patients with diffuse large B-cell lymphoma (DLBCL), who progressed on upfront chemotherapy, have a dismal survival of 6.3 months based on the results of the international SCHOLAR-1 study, as noted by Georg Lenz, MD, of the...
By Basem M. William, MD We have made significant progress in our understanding of the pathogenesis and progression of lymphoma through the molecular dissection of malignant cells. By contrast, the importance of the cellular context in which these malignant cells arise...
By Basem M. William, MD Since Thomas Hodgkin’s initial characterization of lymphomas in 1832 and the first administration of mustard to a patient with lymphoma 100 years later amid the secrecy of a World War II gas program, much has changed. Multiple recurrent themes...
